All In Biotech

Drug Trial Radar · NCT02322333

MLD10 in the Prevention of Migraine in Adults

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of MLD10 in the Prevention of Migraine Headache in Adults

Last checked: Nov 19, 2026Latest source record: Oct 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

157

Actual

Start

Mar 2015

Primary completion

Jun 2017

Study completion Jun 2017

Sponsor

Lead sponsor
Pharmalyte Solutions LLCIndustry
Sponsor type
Industry
Collaborators
Clinvest
First posted
Dec 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm their diagnosis, as well as establish baseline migraine characteristics. During this baseline period, subjects will continue treating their migraines as usual, simply recording the information in a daily headache diary. Subjects who, after completing the baseline, continue to meet entrance criteria will be eligible to enter into the treatment phase and be randomized according to the Clinvest generated randomization schedule. Approximately 142 subjects (71 subjects per arm) will be randomized and enter the treatment phase receiving MLD10 or placebo in a 1:1 design at 6 United States sites. Diary assessments will collect study medication adherence, pain severity, headache symptoms, acute medication usage, and unusual symptoms. Serum samples will be collected and analyzed for ionized magnesium, electrolytes, and creatinine.

Conditions

  • Migraine

Interventions

  • MLD10Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Migraine Headache DaysTime frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • The Research Center of Southern California

    Carlsbad, California

  • San Francisco Clinical Research Center

    San Francisco, California

  • Physician Associates of Florida Research Department

    Oviedo, Florida

  • Dr. B. Abraham, P.C.

    Snellville, Georgia

  • Westside Family Medical Center, P.C.

    Kalamazoo, Michigan

  • StudyMetrix Research

    City of Saint Peters, Missouri

  • Clinvest Research, LLC

    Springfield, Missouri

  • Baptist Memorial Hospital

    Memphis, Tennessee

  • Nashville Neuroscience Group

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.